Physician profile
Jennifer Mulhern
NPI 1699062513
$8,178.33
in general payments reported to CMS, 2019-2025
14 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what 83% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $2,939 · 2021: $89.19 · 2022: $471 · 2023: $384 · 2024: $2,148 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,420 · Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,419.79 |
| Food and Beverage | $2,131.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,710.89 | 2020-2025 | |
| Novus Surgical Consultants | $2,247.85 | 2022-2025 | |
| Stryker Corporation | $1,332.54 | 2019-2025 | Augment Injectable, Infinity Adaptis, Allopure |
| Smith+Nephew, INC. | $227.11 | 2023-2025 | Oasis, Oasis Micro, Stravix Pl |
| Abbott Laboratories | $142.24 | 2023 | Proclaim |
| Averitas Pharma INC. | $139.38 | 2023-2024 | Qutenza |
| Novus Surgical Solutions LLC | $107.99 | 2022 | |
| Merck Sharp & Dohme LLC | $93.61 | 2019 | |
| Inari Medical, INC. | $52.65 | 2021 | |
| Organogenesis INC. | $38.63 | 2020-2024 | Affinity |
| Celularity INC. | $26.50 | 2020 | |
| Solventum Corporation | $22.46 | 2025 | Activ.A.C. |
| Novastep INC. | $19.11 | 2022 | |
| Djo, LLC | $17.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mulhern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.